News | November 12, 2021
Covaxin well tolerated with no safety concerns: Lancet
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
The company expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021
The ground-breaking project, led by Genomics England and NHS England, was established in 2013 to sequence 100,000 whole genomes from NHS patients and their families
The company will provide the technical and financial resources to support the study
_256_384.png)
Cryoballoon catheter ablation, a minimally invasive procedure, is one of the therapeutic modalities to manage Atrial fibrillation
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
The workshop had been organized by the department of surgery at Jawaharlal Nehru Medical College (JNMC), Aligarh Muslim University (AMU), along with the Association of Surgeons of Aligarh (ASA)
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
Subscribe To Our Newsletter & Stay Updated
